Endeavor BioMedicines, Inc., a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical benefits to patients with life-threatening diseases, announced the closing of a $132.5 million Series C financing, including the conversion of a $5 million convertible instrument.

Endeavor BioMedicines，Inc.，一家临床阶段生物技术公司，开发有可能为危及生命的疾病患者提供转化性临床益处的药物，宣布关闭1.325亿美元的C系列融资，包括转换500万美元的可转换工具。

The oversubscribed round was led by AyurMaya, an affiliate of Matrix Capital Management, with participation from new investors including Fidelity Management & Research Company, Invus, SymBiosis, Velosity Capital, and Woodline Partners; and strong support from existing investors including funds managed by abrdn Inc.

超额认购由矩阵资本管理公司的附属公司AyurMaya牵头，新投资者包括Fidelity Management&Research Company、Invus、SymBiosis、Velosity Capital和Woodline Partners；以及包括abrdn Inc.管理的基金在内的现有投资者的大力支持。

(formerly Tekla Capital Management LLC), Ally Bridge Group, Avidity Partners, Eckuity Capital, Longitude Capital, Omega Funds, Perceptive Advisors, Piper Heartland Healthcare Capital, Silver Arch Bio, and T. Rowe Price Associates..

（原Tekla Capital Management LLC）、Ally Bridge Group、Avidity Partners、Eckuity Capital、Longitude Capital、Omega Funds、Perceptive Advisors、Piper Heartland Healthcare Capital、Silver Arch Bio和T.Rowe Price Associates。